Basic information Safety Related Supplier

ChemicalBook Product Catalog Minalrestat

1/1

Minalrestat NEW

$258.00 1mg

$642.00 5mg

$913.00 10mg

Min. Order
Purity99.88%
Cas No129688-50-2
Supply Ability10g
Update time2026-04-14

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Minalrestat
CAS No	129688-50-2
EC-No
Min. Order
Purity	99.88%
Supply Ability	10g
Release date	2026/04/14

Product Introduction

Bioactivity

Name	Minalrestat
Description	Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.
In vitro	Minalrestat (100 μM) reduces intracellular sorbitol content in primary cultured rat cells without affecting intracellular glucose levels.[3] Minalrestat (100 μM, 48 h) causes the accumulation of PKC-α and -β2 in primary cultured rat mesangial cells.[3]
In vivo	The diabetic group was treated from 3 days after the alloxan injection with Minalrestat (10 mg/kg/day) for 30 days and the Minalrestat treatment (10 mg/kg/day/7 days) of galactosemic rats started concomitantly with the induction of galactosemia. The impaired responses to bradykinin, histamine, and platelet-activating factors of arterioles and venules observed in diabetic and galactosemic rats were completely prevented by Minalrestat. Neither diabetes nor galactosemia affected responses to acetylcholine and sodium nitroprusside. Responses to these agents were not modified by aldose reductase inhibition. The restoring effect of Minalrestat was reversed by inhibition of nitric oxide (NO) synthesis with N(omega)-nitro-L-arginine methyl ester, by blocking K(+) channel with tetraethylammonium but not by cyclooxygenase inhibition with diclofenac.[1]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 45 mg/mL (100.18 mM), Sonication is recommended.
Keywords	WAY-ARI509 \| WAYARI509 \| WAY-ARI 509 \| WAYARI 509 \| WAY 121509 \| Minalrestat \| ARI 509 \| Aldose reductase
Inhibitors Related	FH1 \| Furaneol \| Epalrestat \| 2-Chloro-1-(4-fluorobenzyl)benzimidazole \| Dicoumarol \| 4-hydroxyphenyl acetate \| Lapisteride \| Alpha-Estradiol \| Finasteride \| Isoliquiritigenin \| AKR1C1-IN-1 \| Kopexil
Related Compound Libraries	Glycometabolism Compound Library \| Bioactive Compound Library \| Anti-Diabetic Compound Library \| Inhibitor Library \| Orally Active Compound Library \| Metabolism Compound Library \| Bioactive Compounds Library Max \| Fluorochemical Library

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy